We are live on ! Find out more
PTC

Philadelphia Trust Company Portfolio holdings

AUM $1.42B
1-Year Est. Return 43.77%
This Fund
S&P 500
This Quarter Est. Return
+5.13%
1 Year Est. Return
+43.77%
3 Year Est. Return
+141.5%
5 Year Est. Return
+176.17%
10 Year Est. Return
+554.31%
AUM
$1.27B
AUM Growth
+$54.2M
Cap. Flow
+$6.03M
Cap. Flow %
0.47%
Top 10 Hldgs %
30.4%
Holding
230
New
24
Increased
67
Reduced
66
Closed
9

Top Sells

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$16.4M
2
TWX
Time Warner Inc
TWX
+$13.7M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$8.56M
4
TSN icon
Tyson Foods
TSN
+$7.59M
5
QCOM icon
Qualcomm
QCOM
+$7.49M

Sector Composition

Rank Sector Weight
1 Technology 22.68%
2 Financials 19.47%
3 Healthcare 12.46%
4 Communication Services 9.96%
5 Industrials 9.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
REGN icon
226
Regeneron Pharmaceuticals
REGN
$80.8B
-19,136
Closed -$8.56M
COL
227
DELISTED
Rockwell Collins
COL
-27,600
Closed -$3.61M

Similar funds

Philadelphia Trust Company's Q4 2017 Portfolio in Review

As of Q4 2017, Philadelphia Trust Company held 230 positions worth $1.27B, up 4.5% from $1.22B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Philadelphia Trust Company's Q4 2017 filing shows 24 new, 67 increased, 66 reduced and 9 closed positions. Its largest new stake was State Street SPDR Portfolio Intermediate Term Corporate Bond ETF: 175,285 shares worth $6M. The largest sale was CVS Health, an estimated $16.4M.

By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 22% a quarter earlier, followed by Financials and Healthcare.

  • Philadelphia Trust Company's largest Q4 2017 buy was State Street SPDR Portfolio Intermediate Term Corporate Bond ETF: 175,285 shares worth $6M.
  • Philadelphia Trust Company added most to Emerson Electric in Q4 2017, an estimated $10.5M increase.
  • Philadelphia Trust Company's biggest Q4 2017 reduction was CVS Health, cutting an estimated $16.4M.
  • Philadelphia Trust Company fully exited Regeneron Pharmaceuticals in Q4 2017, selling an estimated $8.56M.
  • Philadelphia Trust Company's ten largest holdings make up 30% of its $1.27B portfolio in Q4 2017.
  • Philadelphia Trust Company opened 24 new positions and closed 9 in Q4 2017.
  • Philadelphia Trust Company's portfolio value rose 4.5% quarter-over-quarter to $1.27B.

Based on Philadelphia Trust Company's 13F filing for Q4 2017, filed 14 Feb 2018.